Internal Medicine, Nephrology · Bronx, NY
NPI
1427459734
Since 2014
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
600 E 233rd St
Bronx, NY, 10466
Phone (718) 920-9880
Groups this clinician bills Medicare through
Medicare paid, 2024
$375K
11,479 services
Medicare patients, 2024
261
Average age 78
Drug cost, 2024
$3.2M
4,543 prescriptions
Company payments, 2025
$48K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John S Kang was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 1,119 times for 218 patients. In total John S Kang billed 11,479 services in 68 codes, and Medicare paid $375K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-06-01.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,119 | 218 | $13.97 | $16K |
| 99214 Office E&M - Established | Office | 944 | 218 | $109.85 | $104K |
| 36415 Venipuncture Blood Collection | Office | 570 | 198 | $8.65 | $4,931 |
| 99213 Office E&M - Established | Office | 556 | 178 | $77.61 | $43K |
| 84100 Clinical Chemistry | Office | 549 | 196 | $4.65 | $2,553 |
| 80048 Clinical Chemistry | Office | 549 | 196 | $8.29 | $4,551 |
| 80076 Clinical Chemistry | Office | 545 | 196 | $8.01 | $4,365 |
| 85025 Blood Count | Office | 543 | 196 | $7.61 | $4,132 |
| 84550 Clinical Chemistry | Office | 503 | 194 | $4.43 | $2,228 |
| 83735 Clinical Chemistry | Office | 462 | 187 | $6.57 | $3,035 |
| 80061 Clinical Chemistry | Office | 437 | 196 | $13.12 | $5,733 |
| 83721 Clinical Chemistry | Office | 433 | 196 | $10.29 | $4,456 |
| 82728 Clinical Chemistry | Office | 413 | 170 | $13.36 | $5,518 |
| 83036 Blood Count | Office | 407 | 184 | $9.52 | $3,875 |
| 83550 Clinical Chemistry | Office | 392 | 160 | $8.57 | $3,359 |
By year: 2022 $84K for 895 services; 2023 $162K for 2,552 services; 2024 $375K for 11,479 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 570 | 198 | $8.65 | $4,931 |
| 84100 Clinical Chemistry | 549 | 196 | $4.65 | $2,553 |
| 80048 Clinical Chemistry | 549 | 196 | $8.29 | $4,551 |
| 80076 Clinical Chemistry | 545 | 196 | $8.01 | $4,365 |
| 85025 Blood Count | 543 | 196 | $7.61 | $4,132 |
| 84550 Clinical Chemistry | 503 | 194 | $4.43 | $2,228 |
| 83735 Clinical Chemistry | 462 | 187 | $6.57 | $3,035 |
| 80061 Clinical Chemistry | 437 | 196 | $13.12 | $5,733 |
| 83721 Clinical Chemistry | 433 | 196 | $10.29 | $4,456 |
| 82728 Clinical Chemistry | 413 | 170 | $13.36 | $5,518 |
Medicare prescription drug claims, 2024
In 2024, the drug John S Kang prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 355 prescriptions and refills. In total John S Kang wrote 4,543 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 355 | 504 | 86 | $278K |
| Losartan Potassium Generic | 316 | 664 | 101 | $3,576 |
| Amlodipine Besylate Generic | 304 | 632 | 95 | $2,165 |
| Kerendia Finerenone | 249 | 281 | 40 | $173K |
| Nifedipine Er Nifedipine | 247 | 465 | 59 | $5,735 |
| Chlorthalidone Generic | 237 | 462 | 75 | $4,634 |
| Furosemide Generic | 152 | 280 | 44 | $896 |
| Lokelma Sodium Zirconium Cyclosilicate | 134 | 158 | 29 | $142K |
| Rosuvastatin Calcium Generic | 134 | 324 | 44 | $2,222 |
| Tamsulosin Hcl Generic | 125 | 311 | 44 | $2,203 |
| Lisinopril Generic | 116 | 252 | 38 | $725 |
| Atorvastatin Calcium Generic | 106 | 238 | 30 | $960 |
| Veltassa Patiromer Calcium Sorbitex | 101 | 106 | 21 | $112K |
| Allopurinol Generic | 99 | 243 | 27 | $1,037 |
| Jardiance Empagliflozin | 94 | 136 | 26 | $79K |
Brand drugs: 1,511 claims; generic drugs: 3,015 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John S Kang $48K ($48K in general payments such as food, travel and fees) from 19 companies. The largest payer was Calliditas Therapeutics US Inc. with $26K.
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 46 | $26K |
| Amgen Inc. AMGN | 75 | $18K |
| ANI Pharmaceuticals, Inc. ANIP | 28 | $367 |
| Travere Therapeutics, Inc. TVTX | 14 | $312 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $232 |
| Novo Nordisk Inc NVO | 7 | $221 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 11 | $206 |
| Ascendis Pharma Endocrinology Inc ASND | 7 | $202 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 6 | $195 |
| Vifor Pharma, Inc. | 13 | $191 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.